For decades, decisions about cholesterol treatment hinged on a simple question: What is this person’s risk of a heart attack or stroke in the next 10 years? The answer usually mattered most in midlife. Now, clinicians are being asked to consider longer-term risk—sometimes starting in a person’s 30s.
Under the new 2026
cholesterol guidelines published by the American College of Cardiology and the American Heart Association, you may be sent for more tests. You could leave with a statin—not because you are sick today, but because you might develop heart disease in 30 years.
The 2026 guidelines add layers to what was once a simpler decision. Instead of focusing mainly on short-term risk, doctors are asked to calculate both 10- and 30-year risk, weigh “risk enhancers” such as family history or inflammation, and, in some cases, add tests such as lipoprotein(a) or coronary calcium scans.
A healthy 32-year-old with a low-density lipoprotein cholesterol level of 160 and a family history of heart disease may now be told to consider medication, even if the short-term risk is low. Screening starts earlier, too. The guidelines recommend cholesterol testing for all children aged 9 to 11, and as early as age 2 for those with a strong family history or inherited disorders.
A visit that once centered on a single number now pulls in age, blood pressure, smoking status, diabetes, and a long-term risk score calculated using a tool called PREVENT. From there, testing can expand. A blood test may check for lipoprotein(a), a genetic risk factor carried by about one in five adults. A calcium scan may look for plaque building silently in the arteries.
The guidelines also set new, specific targets for low-density lipoprotein cholesterol, the so-called bad cholesterol. Targets are often below 100, 70, or even 55, with treatment adjusted over time to keep levels low. Over the years, these levels have kept moving lower and lower so that drug therapy can begin earlier and earlier. Under the innocuous cover of prevention, the medical establishment is now insisting on using drugs rather than lifestyle and diet choices to lower the risk of heart disease. Big Pharma appears to have influenced medical standards once again.
This is especially so when one considers the benefit of statin drugs in preventing heart disease is miniscule. The absolute risk reduction in heart disease after taking a statin for ten years is a measly 0.5%. That translates to roughly 1 or 2 people out of 200 taking a statin drug might avoid a heart attack or stroke over ten years. The cumulative side effects of taking a synthetic, toxic drug for a decade are never considered or addressed.
For more detailed information on the games Big Pharma plays with cholesterol see these two blog articles and two WSG webinars:
Blog Article 1
Blog Article 2
WSG Webinar 1
WSG Webinar 2
